Identification

Name
Aranidipine
Accession Number
DB09229
Type
Small Molecule
Groups
Approved, Investigational
Description

Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity. It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate.[1] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[5]

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Sapresta
Categories
UNII
4Y7UR6X2PO
CAS number
86780-90-7
Weight
Average: 388.376
Monoisotopic: 388.127050992
Chemical Formula
C19H20N2O7
InChI Key
NCUCGYYHUFIYNU-UHFFFAOYSA-N
InChI
InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3
IUPAC Name
3-methyl 5-(2-oxopropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)=O

Pharmacology

Indication

Aranidipine has been used for many years to treat angina pectoris and hypertension.[1]

Pharmacodynamics

Pre-clinical studies with aranidipine and its two metabolites have shown production of increases in femoral blood flow. It has been shown to present potent and long-lasting vasodilating actions. Aranidipine and its metabolites are shown to inhibit calcium-induced contraction in isolated rabbit arteries.[1] Studies have shown that aranidipine is more potent to reduce blood pressure than other dihydropyridines.[2] Aranidipine produce changes in renal blood flow, this effect may be explained by its effect on alpha-2-adrenoreceptor-mediated vasoconstriction.[4]

Mechanism of action

The high potential of aranidipine is thought to be related to the additional calcium antagonistic activity of its metabolite. The mechanism is thought to be related to the capacity of aranidipine and its metabolites to vasodilate afferent and efferent arterioles. this action is performed through the inhibition of voltage-dependent calcium channels.[2] The typical mechanism of action of aranidipine, as all dihydropyridines, is based on the inhibition of L-type calcium channels, decreasing calcium concentration and inducing smooth muscle relaxation.[3] It is a selective alpha2-adrenoreceptor antagonist which inhibits vasoconstrictive responses.[5]

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
antagonist
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
antagonist
Human
AVoltage-dependent L-type calcium channel subunit alpha-1F
antagonist
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
antagonist
Human
UAlpha adrenergic receptor
agonist
Human
Absorption

After administration, aranidipine is rapidly absorbed from the gastrointestinal tract. After absorption, the AUC and Cmax increased linearly in a dose-dependent manner, the Cmax was attained in approximate 3.8-4.8 hours for aranidipine and 4.8-6 hours for the metabolite M-1. The bioavailability of aranidipine in rat, dog, and monkey was about 48%, 41% and 3% respectively.[6]

Volume of distribution
Not Available
Protein binding

The binding ratio of plasma proteins of aranidipine varies from 84-95%. This ratio of the drug is similar to the unchanged form and for the M-1 metabolite. Most of the binding happens towards serum albumin and a lower amount corresponds to the alpha1-acid glycoprotein.[6]

Metabolism

Eight metabolites of aranidipine were found after oral administration. These metabolites were brought by a reduction of the ketone group, oxidation of dihydropyridine ring and de-esterification at the C-3 position.[6]

Route of elimination

Unchanged aranidipine is found in plasma but not in the urine after 1 hour of administration. Just a small amount of drug was found in the bile. These results indicate that the excretion profile of aranidipine is mainly driven by metabolism and not by excretion. When including the metabolites, 52-56% of the original dose is disposed in the urine, 34-45% in feces and 3-4% in expired air. The excretion in the bile was 59% of the administered dose and 63% of this portion is reabsorbed.[6]

Half life

The elimination half-life of aranidipine and the M-1 metabolite are 1.1-1.2 hour and 2.7-3.5 hour respectively.[6]

Clearance
Not Available
Toxicity

In toxicity studies performed in mice, rats, and beagles there was a reported LD50 of 143 mg/kg, 1982 mg/kg and 4000 mg/kg respectively. In repeated dose studies, some of the reported side effects included increased urinary volume, serum lipid, urea nitrogen, liver weight, decreased urinary osmotic pressure and hypertrophy of hepatocytes. Teratogenic studies showed a slight generation of fetal visceral abnormalities. Other toxicity studies showed no effects on fetal development, reproductive ability, genotoxic, allergenic, or oncogenic potential.[6]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Aranidipine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Aranidipine.Vet Approved
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Aranidipine.Approved, Vet Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Aranidipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Aranidipine.Approved
AmobarbitalThe metabolism of Aranidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Aranidipine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Aranidipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Aranidipine.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Aranidipine.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Aranidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Aranidipine.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Aranidipine.Approved
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Aranidipine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Aranidipine.Experimental
BarbexacloneThe metabolism of Aranidipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Aranidipine can be increased when combined with Barbital.Illicit
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Aranidipine.Approved, Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Aranidipine.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Aranidipine.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Aranidipine.Experimental
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Aranidipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Aranidipine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Aranidipine.Investigational
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Aranidipine.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Aranidipine.Approved
Calcium AcetateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Aranidipine.Withdrawn
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Aranidipine.Experimental
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Aranidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Aranidipine.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Aranidipine.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Aranidipine.Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Aranidipine.Approved, Investigational, Vet Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Aranidipine.Approved, Investigational
CimetidineThe serum concentration of Aranidipine can be increased when it is combined with Cimetidine.Approved, Investigational
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Aranidipine.Approved
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Aranidipine.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Aranidipine.Approved
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Aranidipine.Investigational
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Aranidipine.Approved, Investigational, Vet Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Aranidipine.Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Aranidipine.Approved, Illicit
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Aranidipine.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Aranidipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Aranidipine.Approved, Investigational
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Aranidipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Aranidipine.Approved, Vet Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Aranidipine.Approved
EfavirenzThe serum concentration of Aranidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Aranidipine.Approved
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Aranidipine.Approved, Vet Approved
EscitalopramThe risk or severity of hypotension can be increased when Escitalopram is combined with Aranidipine.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Aranidipine.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Aranidipine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Aranidipine.Approved, Investigational
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Aranidipine.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Aranidipine.Experimental
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Aranidipine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Aranidipine.Approved, Investigational, Vet Approved
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Aranidipine.Experimental
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Aranidipine.Approved, Withdrawn
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Aranidipine.Approved, Investigational
HexobarbitalThe metabolism of Aranidipine can be increased when combined with Hexobarbital.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Aranidipine.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Aranidipine.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Aranidipine.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Aranidipine.Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Aranidipine.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Aranidipine.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Aranidipine.Approved
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Aranidipine.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Aranidipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Aranidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Aranidipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Aranidipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Aranidipine.Experimental
MethohexitalThe metabolism of Aranidipine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Aranidipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Aranidipine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Aranidipine.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Aranidipine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Aranidipine.Approved, Investigational, Vet Approved
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Aranidipine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Aranidipine.Vet Approved
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Aranidipine.Experimental
NafcillinThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Aranidipine.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Aranidipine.Approved
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Aranidipine.Approved, Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Aranidipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Aranidipine.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Aranidipine.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Aranidipine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Aranidipine.Investigational
NitroprussideAranidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Aranidipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Aranidipine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Aranidipine.Approved, Vet Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Aranidipine.Approved, Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Aranidipine.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Aranidipine.Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Aranidipine.Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Aranidipine.Approved
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Aranidipine.Approved, Investigational
PentobarbitalThe metabolism of Aranidipine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Aranidipine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Aranidipine.Approved
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Aranidipine.Approved
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Aranidipine.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Aranidipine.Approved, Investigational, Vet Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Aranidipine.Approved
PrimidoneThe metabolism of Aranidipine can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Aranidipine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Aranidipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Aranidipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Aranidipine.Approved, Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Aranidipine.Experimental
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Aranidipine.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Aranidipine.Approved, Investigational
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Aranidipine.Approved
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Aranidipine.Experimental
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Aranidipine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Aranidipine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Aranidipine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Aranidipine.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Aranidipine.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Aranidipine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Aranidipine.Approved, Investigational, Vet Approved
SecobarbitalThe metabolism of Aranidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Aranidipine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Aranidipine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Aranidipine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Aranidipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Aranidipine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Aranidipine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Aranidipine.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Aranidipine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Aranidipine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Aranidipine.Approved
ThiamylalThe metabolism of Aranidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Aranidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Aranidipine.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Aranidipine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Aranidipine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Aranidipine.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Aranidipine.Approved, Vet Approved
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Aranidipine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Aranidipine.Approved, Investigational, Vet Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Aranidipine.Approved, Investigational
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Aranidipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Aranidipine.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Aranidipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Aranidipine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Aranidipine.Investigational
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Aranidipine.Approved
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Aranidipine.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Aranidipine.Experimental
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Aranidipine.Approved
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Aranidipine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Miyoshi K, Miyake H, Ichihara K, Kamei H, Nagasaka M: Contribution of aranidipine metabolites with slow binding kinetics to the vasodilating activity of aranidipine. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jan;355(1):119-25. [PubMed:9007851]
  2. Nakamura A, Hayashi K, Fujiwara K, Ozawa Y, Honda M, Saruta T: Distinct action of aranidipine and its active metabolite on renal arterioles, with special reference to renal protection. J Cardiovasc Pharmacol. 2000 Jun;35(6):942-8. [PubMed:10836731]
  3. Dhein S, Salameh A, Berkels R, Klaus W: Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs. 1999 Sep;58(3):397-404. [PubMed:10493269]
  4. Miyoshi K, Kanda A, Nozawa Y, Nakano M, Miyake H: Regional vascular effects of MPC-1304, a novel dihydropyridine derivative, in conscious normotensive and spontaneously hypertensive rats. J Pharmacol Exp Ther. 1996 Jun;277(3):1328-36. [PubMed:8667194]
  5. Allen R. (1988). Annual reports in medicinal chemistry (23rd ed.). Academic press.
  6. Researchgate [Link]
External Links
KEGG Drug
D01562
PubChem Compound
2225
PubChem Substance
310265133
ChemSpider
2139
ChEBI
31232
ChEMBL
CHEMBL2104030
Wikipedia
Aranidipine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149-150ºCOhasi and Ebihara. (1996). Cardiovascular Drugs Review.
water solubilityInsolubleOhasi and Ebihara. (1996). Cardiovascular Drugs Review.
Predicted Properties
PropertyValueSource
Water Solubility0.0112 mg/mLALOGPS
logP2.71ALOGPS
logP1.62ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)16.8ChemAxon
pKa (Strongest Basic)-6.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area124.84 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity100.8 m3·mol-1ChemAxon
Polarizability38.31 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Alpha-acyloxy ketones / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Ketones / Organic oxoazanium compounds
show 7 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Alpha-acyloxy ketone / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide / Methyl ester / Alpha,beta-unsaturated carboxylic ester
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. KEGG [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. KEGG [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1F
Uniprot ID
O60840
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1F
Molecular Weight
220675.9 Da
References
  1. KEGG [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. KEGG [Link]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Miyoshi K, Kanda A, Nozawa Y, Nakano M, Miyake H: Regional vascular effects of MPC-1304, a novel dihydropyridine derivative, in conscious normotensive and spontaneously hypertensive rats. J Pharmacol Exp Ther. 1996 Jun;277(3):1328-36. [PubMed:8667194]

Enzymes

Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...

Components:
References
  1. KEGG [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Researchgate [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Binder
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Researchgate [Link]

Drug created on October 23, 2015 10:10 / Updated on July 02, 2018 19:13